Growth and genetic characteristics of clinical-grade MSCs
| Culture protocol/donor number (age, y) . | PD (proliferation rate)* . | Karyotype P1 (no. of mitoses) . | Karyotype P2 (no. of mitoses) . | hTERT P1 . |
|---|---|---|---|---|
| FCS/FGF-2 | ||||
| 1A (55) | 23 (29.5) | 46, XX (15) | ND | Negative |
| 2A (38) | 23 (209.2) | 46, XX (17) | 46, XX (21) | Negative |
| 3A (32) | 22 (170.8) | 46, XY (17) | 46, XY (20) | Negative |
| 4A (29) | 20 (145.8) | 46, XX (14) | ND | Negative |
| 5A (41) | 24 (20.9) | 46, XY (16) | ND | Negative |
| 6A (33) | 21 (78.2) | 49, XY, +5, +8, +20 (3)/46, XY (19) | 46, XY (31) | Negative |
| 7A (50) | 19 (4.6) | 46, XY (21) | ND | Negative |
| 8A (30) | 21 (47.9) | 46, XY (6) | 46, XY (21) | Negative |
| 9A (61) | 20 (18.1) | 49, XY, +5, +8, +20 (3)/46, XY (18) | 46, XY (29) | Negative |
| 10A (28) | 19 (39.8) | 46, XY (27) | ND | Negative |
| 11A (48) | 24 (34) | 46, XX (30) | 46, XX (30) | Negative |
| 12A (47) | 22 (44.6) | 47, XX, +5 (15)/46, XX (5) | ND | Negative |
| 13A (56) | 20 (54.2) | 46, XY (20) | ND | Negative |
| 12A2 (47) | 20 (57.5) | 47, XX, +5 (3)/46, XX (17) | 47, XX, +5(2)/46, XX(28) | ND |
| 13A2 (56) | 17 (9.44) | 46, XY (30) | ND | ND |
| Platelet lysate | ||||
| 12B (47) | 18 (6.2) | 46, XX (28)/47, XX, +5 (2) | 47, XX +5(2)/46, XX (28) | Negative |
| 13B (56) | 16 (1.5) | 46, XY (30) | 46, XY (30) | Negative |
| 14B† (27) | 17 (16.2) | 46, XY (30) | 46, XY (30) | Negative |
| 15B† (33) | 15 (1.3) | 46, XY (30) | 46, XY (30) | Negative |
| 16B† (23) | 19 (16.5) | 46, XY (30) | ND | ND |
| Culture protocol/donor number (age, y) . | PD (proliferation rate)* . | Karyotype P1 (no. of mitoses) . | Karyotype P2 (no. of mitoses) . | hTERT P1 . |
|---|---|---|---|---|
| FCS/FGF-2 | ||||
| 1A (55) | 23 (29.5) | 46, XX (15) | ND | Negative |
| 2A (38) | 23 (209.2) | 46, XX (17) | 46, XX (21) | Negative |
| 3A (32) | 22 (170.8) | 46, XY (17) | 46, XY (20) | Negative |
| 4A (29) | 20 (145.8) | 46, XX (14) | ND | Negative |
| 5A (41) | 24 (20.9) | 46, XY (16) | ND | Negative |
| 6A (33) | 21 (78.2) | 49, XY, +5, +8, +20 (3)/46, XY (19) | 46, XY (31) | Negative |
| 7A (50) | 19 (4.6) | 46, XY (21) | ND | Negative |
| 8A (30) | 21 (47.9) | 46, XY (6) | 46, XY (21) | Negative |
| 9A (61) | 20 (18.1) | 49, XY, +5, +8, +20 (3)/46, XY (18) | 46, XY (29) | Negative |
| 10A (28) | 19 (39.8) | 46, XY (27) | ND | Negative |
| 11A (48) | 24 (34) | 46, XX (30) | 46, XX (30) | Negative |
| 12A (47) | 22 (44.6) | 47, XX, +5 (15)/46, XX (5) | ND | Negative |
| 13A (56) | 20 (54.2) | 46, XY (20) | ND | Negative |
| 12A2 (47) | 20 (57.5) | 47, XX, +5 (3)/46, XX (17) | 47, XX, +5(2)/46, XX(28) | ND |
| 13A2 (56) | 17 (9.44) | 46, XY (30) | ND | ND |
| Platelet lysate | ||||
| 12B (47) | 18 (6.2) | 46, XX (28)/47, XX, +5 (2) | 47, XX +5(2)/46, XX (28) | Negative |
| 13B (56) | 16 (1.5) | 46, XY (30) | 46, XY (30) | Negative |
| 14B† (27) | 17 (16.2) | 46, XY (30) | 46, XY (30) | Negative |
| 15B† (33) | 15 (1.3) | 46, XY (30) | 46, XY (30) | Negative |
| 16B† (23) | 19 (16.5) | 46, XY (30) | ND | ND |
Two donors (12 and 13) were collected twice, giving rise to a first MSC expansion performed in FCS/FGF-2 culture condition (12A and 13A) and to a second MSC expansion performed in 2 independent laboratories both in FCS/FGF-2 (12A2 and 13A2) and in platelet lysate (12B and 13B) culture conditions.
PD indicates cumulative number of population doubling (PD at P0 × PD P1); and ND, not done.
Proliferation rate = cumulative proliferation rate (proliferation rate at P0 × proliferation rate at P1).
Autologous MSCs from accidentally irradiated patients.